Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial

Aims To investigate the effect of adding the short‐acting glucagon‐like peptide 1 receptor agonist (GLP‐1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods In a randomized, double‐blind, parallel‐group trial, 108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy with a body mass index >22.0 kg/m 2 and glycated haemoglobin concentration of 59 to 88...